ENTEROME

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

ENTEROME headquartered in Europe, operates in the Biotechnology, Life Science, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $28.9B in funding across 144 round(s). With a team of 51-100 employees, ENTEROME is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - ENTEROME, raised $9.9M. Discover more about their projects, partnerships, and impact on our platform.